Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01231594
Title A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

Advanced Solid Tumor

Therapies

Dabrafenib

Trametinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

Facility Status City State Zip Country Details
Novartis Investigative Site Goodyear Arizona 85338 United States Details
Novartis Investigative Site Scottsdale Arizona 85259 United States Details
Novartis Investigative Site Tucson Arizona 85724-5024 United States Details
Novartis Investigative Site Los Angeles California 90025 United States Details
Novartis Investigative Site Los Angeles California 90095-7059 United States Details
Novartis Investigative Site San Francisco California 94115 United States Details
Novartis Investigative Site Sarasota Florida 34232 United States Details
Novartis Investigative Site Ann Arbor Michigan 48109 United States Details
Novartis Investigative Site Detroit Michigan 48201 United States Details
Novartis Investigative Site Lebanon New Hampshire 03756 United States Details
Novartis Investigative Site New York New York 10016 United States Details
Novartis Investigative Site New York New York 10065 United States Details
Novartis Investigative Site Columbus Ohio 43210 United States Details
Novartis Investigative Site Oklahoma City Oklahoma 73104 United States Details
Novartis Investigative Site Philadelphia Pennsylvania 19111 United States Details
Novartis Investigative Site Pittsburgh Pennsylvania 15232 United States Details
Novartis Investigative Site Greenville South Carolina 29605 United States Details
Novartis Investigative Site Memphis Tennessee 38120 United States Details
Novartis Investigative Site Nashville Tennessee 37203 United States Details
Novartis Investigative Site Nashville Tennessee 37232-5536 United States Details
Novartis Investigative Site Dallas Texas 75246 United States Details
Novartis Investigative Site Houston Texas 77030 United States Details
Novartis Investigative Site San Antonio Texas 78229 United States Details
Novartis Investigative Site Salt Lake City Utah 84112 United States Details
Novartis Investigative Site Tacoma Washington 98405 United States Details
Novartis Investigative Site Randwick New South Wales 2031 Australia Details
Novartis Investigative Site Westmead New South Wales 2145 Australia Details
Novartis Investigative Site Adelaide South Australia 5000 Australia Details
Novartis Investigative Site Heidelberg Victoria 3084 Australia Details
Novartis Investigative Site Melbourne Victoria 3004 Australia Details
Novartis Investigative Site Nedlands Western Australia 6009 Australia Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Lille 59037 France Details
Novartis Investigative Site Essen Nordrhein-Westfalen 45122 Germany Details
Novartis Investigative Site Luebeck Schleswig-Holstein 23538 Germany Details
Novartis Investigative Site Berlin 10117 Germany Details
Novartis Investigative Site Napoli Campania 80131 Italy Details
Novartis Investigative Site Konin 62-500 Poland Details
Novartis Investigative Site Warszawa 02-781 Poland Details
Novartis Investigative Site Barcelona 08035 Spain Details
Novartis Investigative Site Madrid 28040 Spain Details
Novartis Investigative Site Sevilla 41013 Spain Details
Novartis Investigative Site Headington OX3 7LJ United Kingdom Details
Novartis Investigative Site London W1G 6AD United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field